A model for the regulation of T-type Ca2+ channels in proliferation: Roles in stem cells and cancer

Expert Review of Anticancer Therapy

Volumn 13, Issue 5, 2013, Pages 589-595

  Gray, Lloyd S ^a   Schiff, David ^b   Macdonald, Timothy L ^b  

^a Tau Therapeutics LLC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cancer; Cav3.2; cell cycle; membrane potential; potassium channel; proliferation; stem cell; T type calcium channel

Indexed keywords

CALCIUM CHANNEL T TYPE; MIBEFRADIL; TEMOZOLOMIDE;

CALCIUM TRANSPORT; CANCER CELL; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINT; GLIOMA; HUMAN; MEMBRANE POTENTIAL; NONHUMAN; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; STEM CELL;

ANIMALS; CALCIUM; CALCIUM CHANNELS, T-TYPE; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; G1 PHASE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; S PHASE; STEM CELLS;

EID: 84876826531     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.34     Document Type: Review

References (40)

1. Veigl ML, Sedwick WD, Vanaman TC. Calmodulin and Ca2+ in normal and transformed cells. Fed. Proc. 41(7), 2283-2288 (1982).
2. Rustandi RR, Baldisseri DM, Weber DJ. Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 7(7), 570-574 (2000).
3. Lu F, Chen H, Zhou C et al. T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium 43(1), 49-58 (2008).
4. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8(7), 547-566 (2009).
5. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. Bull. Math. Biol. 52, 25-71; discussion 5-23 (1990).
6. Trautwein W, Hescheler J. Regulation of cardiac L-type calcium current by phosphorylation and G proteins. Annu. Rev. Physiol. 52, 257-274 (1990).
7. Saimi Y, Kung C. Ion channel regulation by calmodulin binding. FEBS Lett. 350(2-3), 155-158 (1994).
8. Putney JW Jr. A model for receptor-regulated calcium entry. Cell Calcium 7(1), 1-12 (1986).
9. Smyth JT, Putney JW. Regulation of store-operated calcium entry during cell division. Biochem. Soc. Trans. 40(1), 119-123 (2012).
10. Cahalan MD. STIMulating store-operated Ca2+ entry. Nat. Cell Biol. 11(6), 669-677 (2009).
11. Harper JV, McLatchie L, Perez-Reyes E, Cribbs LL, Shattock MJ, Brooks G. T-type calcium channel expression is necessary for G1-S progression in vascular smooth muscle. Circulation 102, 11-48 (2000).
12. Li W, Zhang SL, Wang N, Zhang BB, Li M. Blockade of T-type Ca2+ channels inhibits human ovarian cancer cell proliferation. Cancer Invest. 96, 864-872 (2011).
13. Densmore JJ, Szabo G, Gray LS. A voltage-gated calcium channel is linked to the antigen receptor in Jurkat T lymphocytes. FEBS Lett. 312(2-3), 161-164 (1992).
14. Santoni G, Santoni M, Nabissi M. Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy. Br. J. Pharmacol. 166(4), 1244-1246 (2012).
15. Zhang Y, Zhang J, Jiang D et al. Inhibition of T-type Ca2+ channels by endostatin attenuates human glioblastoma cell proliferation and migration. Brit. J. Pharmacol. 116, 1247-1260 (2012).
16. Mulgrew CJ, Cove-Smith A, McLatchie LM, Brooks G, Shattock MJ, Hendry BM. Inhibition of human mesangial cell proliferation by targeting T-type calcium channels. Nephron Exp. Nephrol. 113(2), e77-e88 (2009).
17. Rodman DM, Reese K, Harral J et al. Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ. Res. 96(8), 864-872 (2005).
18. Brooks G, Harper JV, Bates SE et al. Over expression of the voltage-gated T-type calcium channel induces vascular smooth muscle cell proliferation. Circulation 100, 1-209 (1999).
19. Taylor JT, Zeng XB, Pottle JE et al. Calcium signaling and T-type calcium channels in cancer cell cycling. World J. Gastroenterol. 14(32), 4984-4991 (2008).
20. Gray LS, Perez-Reyes E, Gomora JC et al. The role of voltage gated T-type Ca2+ channel isoforms in mediating 'capacitative' Ca2+ entry in cancer cells. Cell Calcium 36(6), 489-497 (2004).
21. Rodríguez-Gómez JA, Levitsky KL, López-Barneo J. T-type Ca2+ channels in mouse embryonic stem cells: modulation during cell cycle and contribution to self-renewal. Am. J. Physiol., Cell Physiol. 302(3), C494-C504 (2012).
22. Chen CC, Lamping KG, Nuno DW et al. Abnormal coronary function in mice deficient in α1H T-type Ca2+ channels. Science 302(5649), 1416-1418 (2003).
23. Heady TN, Gomora JC, Macdonald TL, Perez-Reyes E. Molecular pharmacology of T-type Ca2+ channels. Jpn. J. Pharmacol. 85(4), 339-350 (2001).
24. Exton JH. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu. Rev. Pharmacol. Toxicol. 36, 481-509 (1996).
25. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J. Membr. Biol. 154(2), 91-107 (1996).
26. Ouadid-Ahidouch H, Roudbaraki M, Delcourt P, Ahidouch A, Joury N, Prevarskaya N. Functional and molecular identification of intermediate- conductance Ca2+-activated K(+) channels in breast cancer cells: association with cell cycle progression. Am. J. Physiol., Cell Physiol. 287(1), C125-C134 (2004).
27. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25(5), 280-289 (2004).
28. Strobl JS, Wonderlin WF, Flynn DC. Mitogenic signal transduction in human breast cancer cells. Gen. Pharmacol. 26(8), 1643-1649 (1995).
29. Tao R, Lau CP, Tse HF, Li GR. Regulation of cell proliferation by intermediate-conductance Ca2+-activated potassium and volume-sensitive chloride channels in mouse mesenchymal stem cells. Am. J. Physiol. Cell Physiol. 295(5), C1409-C1416 (2008).
30. Kraus RL, Li Y, Gregan Y et al. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J. Pharmacol. Exp. Ther. 335(2), 409-417 (2010).
31. Levitan IB. It is calmodulin after all! Mediator of the calcium modulation of multiple ion channels. Neuron 22(4), 645-648 (1999).
32. Estacion M, Mordan LJ. Expression of voltage-gated calcium channels correlates with PDGF-stimulated calcium influx and depends upon cell density in C3H 10T1/2 mouse fibroblasts. Cell Calcium 14(2), 161-171 (1993).
33. Haverstick DM, Heady TN, Macdonald TL, Gray LS. Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry. Cancer Res. 60(4), 1002-1008 (2000).
34. Panner A, Wurster RD. T-type calcium channels and tumor proliferation. Cell Calcium 40(2), 253-259 (2006).
35. Giles TD. Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists. Clin. Ther. 19(Suppl. A), 27-38 (1997).
36. Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J. Neurooncol. 111(2), 97-102 (2013).
37. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
38. Sheehan JP, Xu Z, Popp B, Kowalski L, Schlesinger D. Inhibition of glioblastoma and enhancement of survival via the use of mibefradil in conjunction with radiosurgery. J. Neurosurg. 118(4), 830-837 (2012).
39. NCBI. EST Profile -CACNA1H. www.ncbi.nlm.nih.gov/UniGene/ ESTProfileViewer.cgi?uglist=Hs.459642
40. NCBI. EST Profile -KCNN2. www.ncbi.nlm.nih.gov/UniGene/ ESTProfileViewer.cgi?uglist=Hs.98280